Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$7.3 - $9.46 $192,398 - $249,327
-26,356 Reduced 20.18%
104,261 $889,000
Q4 2023

Jan 25, 2024

BUY
$7.85 - $11.18 $340,242 - $484,574
43,343 Added 49.66%
130,617 $1.11 Million
Q3 2023

Oct 25, 2023

SELL
$7.91 - $13.27 $295,082 - $495,037
-37,305 Reduced 29.94%
87,274 $890,000
Q2 2023

Jul 26, 2023

SELL
$9.27 - $14.88 $799,036 - $1.28 Million
-86,196 Reduced 40.89%
124,579 $1.62 Million
Q1 2023

Apr 28, 2023

SELL
$8.85 - $13.27 $760,144 - $1.14 Million
-85,892 Reduced 28.95%
210,775 $1.96 Million
Q4 2022

Feb 07, 2023

BUY
$3.18 - $10.91 $98,580 - $338,210
31,000 Added 11.67%
296,667 $3.23 Million
Q3 2022

Oct 28, 2022

BUY
$3.99 - $9.3 $37,905 - $88,350
9,500 Added 3.71%
265,667 $1.07 Million
Q2 2022

Jul 28, 2022

BUY
$6.34 - $9.53 $91,930 - $138,185
14,500 Added 6.0%
256,167 $1.87 Million
Q1 2022

Apr 25, 2022

BUY
$8.16 - $11.33 $61,200 - $84,975
7,500 Added 3.2%
241,667 $2.18 Million
Q4 2021

Jan 27, 2022

BUY
$10.38 - $15.2 $129,750 - $190,000
12,500 Added 5.64%
234,167 $2.63 Million
Q2 2021

Jul 29, 2021

BUY
$16.0 - $20.59 $641,248 - $825,206
40,078 Added 22.07%
221,667 $3.63 Million
Q1 2021

Apr 26, 2021

SELL
$19.16 - $28.09 $19,160 - $28,090
-1,000 Reduced 0.55%
181,589 $3.66 Million
Q4 2020

Jan 26, 2021

BUY
$16.4 - $22.9 $1.06 Million - $1.48 Million
64,500 Added 54.62%
182,589 $3.75 Million
Q3 2020

Oct 27, 2020

SELL
$14.05 - $18.13 $969,450 - $1.25 Million
-69,000 Reduced 36.88%
118,089 $2.08 Million
Q2 2020

Jul 29, 2020

BUY
$9.41 - $16.94 $1.76 Million - $3.17 Million
187,089 New
187,089 $3.17 Million

Others Institutions Holding PROF

About Profound Medical Corp.


  • Ticker PROF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,851,300
  • Market Cap $157M
  • Description
  • Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...
More about PROF
Track This Portfolio

Track Zweig Di Menna Associates LLC Portfolio

Follow Zweig Di Menna Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zweig Di Menna Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zweig Di Menna Associates LLC with notifications on news.